Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.07 USD
802.00 K USD
40.21 M USD
3.24 M
About Interpace Biosciences, Inc.
Sector
Industry
CEO
Thomas W. Burnell
Website
Headquarters
Parsippany
Founded
1986
FIGI
BBG000BDV8X0
Interpace Biosciences, Inc. engages in the development and sale of diagnostic clinical and pharma services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test, ThyGenX, an expanded oncogenic mutation panel that helps identify malignant thyroid nodules, ThyraMIR, which assesses thyroid nodules for risk of malignancy, and RespriDx, a genomic test that helps physicians differentiate metastatic or recurrent lung cancer. The company was founded by John P. Dugan in 1986 and is headquartered in Parsippany, NJ.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IDXG is 3.27 USD — it has increased by 0.62% in the past 24 hours. Watch Interpace Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Interpace Biosciences, Inc. stocks are traded under the ticker IDXG.
IDXG stock has risen by 33.74% compared to the previous week, the month change is a 61.08% rise, over the last year Interpace Biosciences, Inc. has showed a 179.49% increase.
IDXG reached its all-time high on Nov 27, 2000 with the price of 14,200.00 USD, and its all-time low was 0.51 USD and was reached on Dec 27, 2022. View more price dynamics on IDXG chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
IDXG stock is 27.78% volatile and has beta coefficient of −0.43. Track Interpace Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Interpace Biosciences, Inc. there?
Today Interpace Biosciences, Inc. has the market capitalization of 14.40 M, it has decreased by −11.44% over the last week.
Yes, you can track Interpace Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Interpace Biosciences, Inc. is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
IDXG net income for the last quarter is 1.28 M USD, while the quarter before that showed 2.06 M USD of net income which accounts for −37.92% change. Track more Interpace Biosciences, Inc. financial stats to get the full picture.
No, IDXG doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 108.00 employees. See our rating of the largest employees — is Interpace Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Interpace Biosciences, Inc. EBITDA is 6.94 M USD, and current EBITDA margin is 9.54%. See more stats in Interpace Biosciences, Inc. financial statements.
Like other stocks, IDXG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Interpace Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Interpace Biosciences, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Interpace Biosciences, Inc. stock shows the buy signal. See more of Interpace Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.